(Q37677036)

21 August 2017

1 reference

title

Benefit-risk assessment of exenatide in the therapy of type 2 diabetes mellitus (English)

1 reference

21 August 2017

0 references

Baptist Gallwitz

1

1 reference

21 August 2017

publication date

1 February 2010

1 reference

21 August 2017

1 reference

21 August 2017

volume

33

1 reference

21 August 2017

issue

2

1 reference

21 August 2017

page(s)

87-100

1 reference

Fatty acids and insulin modulate myocardial substrate metabolism in humans with type 1 diabetes

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11319130-000000000-00000

The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11319130-000000000-00000

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11319130-000000000-00000

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11319130-000000000-00000

Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes

21 January 2018

1 reference

12 December 2020

Long-acting GLP-1 analogs for the treatment of type 2 diabetes mellitus

1 reference

12 December 2020

Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure

1 reference

12 December 2020

1 reference

12 December 2020

Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes

1 reference

12 December 2020

The incretin concept today

1 reference

12 December 2020

GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice

1 reference

12 December 2020

Effects of intravenous glucagon-like peptide-1 on glucose control and hemodynamics after coronary artery bypass surgery in patients with type 2 diabetes

1 reference

12 December 2020

Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas

1 reference

12 December 2020

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

1 reference

12 December 2020

Beta cell mass in diabetes: a realistic therapeutic target?

1 reference

12 December 2020

Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes

1 reference

12 December 2020

Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data

1 reference

12 December 2020

BIM-51077, a dipeptidyl peptidase-IV-resistant glucagon-like peptide-1 analog.

1 reference

12 December 2020

Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005.

1 reference

12 December 2020

The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients.

1 reference

12 December 2020

UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group.

1 reference

12 December 2020

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

1 reference

12 December 2020

Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes

1 reference

12 December 2020

Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus.

1 reference

12 December 2020

1 reference

12 December 2020

Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled tr

1 reference

12 December 2020

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

1 reference

12 December 2020

Therapies for the treatment of type 2 diabetes mellitus based on incretin action.

1 reference

12 December 2020

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

1 reference

12 December 2020

A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study.

1 reference

12 December 2020

Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells.

1 reference

12 December 2020

Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue

1 reference

12 December 2020

Medical antihyperglycaemic treatment of type 2 diabetes mellitus: update of the evidence-based guideline of the German Diabetes Association

1 reference

12 December 2020

Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion

1 reference

12 December 2020

Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus

1 reference

12 December 2020

Exenatide sensitizes insulin-mediated whole-body glucose disposal and promotes uptake of exogenous glucose by the liver

1 reference

12 December 2020

Exenatide: a new option for the treatment of type 2 diabetes

1 reference

12 December 2020

Exenatide and rare adverse events

1 reference

12 December 2020

Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance.

1 reference

12 December 2020

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

1 reference

12 December 2020

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

1 reference

12 December 2020

Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide

1 reference

12 December 2020

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

12 December 2020

Dose-response for glycaemic and metabolic changes 28 days after single injection of long-acting release exenatide in diabetic fatty Zucker rats

1 reference

12 December 2020

Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes

1 reference

12 December 2020

The biology of incretin hormones

1 reference

12 December 2020

Exenatide and rare adverse events

1 reference

12 December 2020

Diabetes and obesity: the twin epidemics

1 reference

12 December 2020

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

1 reference

12 December 2020

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study

1 reference

12 December 2020

Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 diabetes.

1 reference

12 December 2020

Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model

1 reference

12 December 2020

Islet beta cell failure in type 2 diabetes

1 reference

12 December 2020

Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes

1 reference

12 December 2020

Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-b

1 reference

12 December 2020

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

1 reference

12 December 2020

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

1 reference

12 December 2020

10.2165/11319130-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

21 August 2017

1042292875

0 references

1 reference